Adherence and Safety of Intravenous Inebilizumab for NMOSD: Real-world Evidence from China (P6-1.006)

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1A Real-world Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: One-year Follow up Results (P6-1.004)2026
2. 2A Real-world Survey on Medication Satisfaction of Inebilizumab in Chinese Patients with NMOSD (P7-1.011)2026
3. 3Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan2026
4. 4Inebilizumab for Treatment of NMOSD in a Real-world Cohort: Analysis from the SPHERES Registry (P3-1.012)2026
5. 5Inebilizumab in AQP4 ‐Seropositive NMOSD : One‐Year Follow‐Up From a Multicenter, Real‐World Study2026